Globus Medical (GMED)vsMerck & Company Inc (MRK)
GMED
Globus Medical
$90.18
+2.72%
HEALTHCARE · Cap: $11.91B
MRK
Merck & Company Inc
$109.18
+2.73%
HEALTHCARE · Cap: $274.03B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 2112% more annual revenue ($65.01B vs $2.94B). MRK leads profitability with a 28.1% profit margin vs 18.3%. GMED appears more attractively valued with a PEG of 1.73. GMED earns a higher WallStSmart Score of 72/100 (B).
GMED
Strong Buy72
out of 100
Grade: B
MRK
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+40.9%
Fair Value
$149.32
Current Price
$90.18
$59.14 discount
Margin of Safety
-16.2%
Fair Value
$96.56
Current Price
$109.18
$12.62 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 437.0% YoY
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Strong operational efficiency at 24.4%
Revenue surging 25.7% year-over-year
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : GMED
The strongest argument for GMED centers on EPS Growth, Altman Z-Score, Price/Book. Profitability is solid with margins at 18.3% and operating margin at 24.4%. Revenue growth of 25.7% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bear Case : GMED
The primary concerns for GMED are PEG Ratio.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
GMED profiles as a growth stock while MRK is a value play — different risk/reward profiles.
GMED carries more volatility with a beta of 1.09 — expect wider price swings.
GMED is growing revenue faster at 25.7% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
GMED scores higher overall (72/100 vs 59/100), backed by strong 18.3% margins and 25.7% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Globus Medical
HEALTHCARE · MEDICAL DEVICES · USA
Globus Medical, Inc., a medical device company, develops and markets healthcare solutions for patients with musculoskeletal disorders. The company is headquartered in Audubon, Pennsylvania.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?